FDA approves new first-line treatments for 3 cancers

The FDA has approved new first-line treatment options for adults with certain HER2-positive gastric, gastroesophageal junction and esophageal cancers. The agency approved Ziihera in combination with Tevimbra and fluoropyrimidine- and platinum-containing chemotherapy for adults with HER2-positive, unresectable, locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma, according to an Aug. 25 FDA news release. […] The post FDA approves new first-line tre...